Trial Profile
Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Zoledronic acid (Primary)
- Indications Advanced breast cancer; Bone metastases; Carcinoma
- Focus Adverse reactions
- 19 Nov 2020 Status changed from active, no longer recruiting to completed.
- 04 Feb 2020 Planned End Date changed from 1 Nov 2020 to 31 Jan 2021.
- 04 Feb 2020 Planned primary completion date changed from 1 Nov 2019 to 31 Jan 2021.